겸상 적혈구증 치료 시장 : 약제 종류별(Hydroxyurea, Oxybryta, Adakveo, 기타), 유형별(겸상 적혈구 빈혈, HbSC, 기타), 투여 경로별(경구, 비경구) - 세계 기회 분석 및 산업 예측(2021-2031년)

The global sickle cell disease treatment market was valued at $ 1,078.88 million in 2021 and is projected to reach $1,618.78million by 2031, registering a CAGR of 4.1% from 2022 to 2031. 

The round and healthy red blood cells move through small blood channels to deliver oxygen to every part of the body. In sickle cell disease patients, the hemoglobin is abnormal, which causes the red blood cells get transformed into C-shaped cells called as a sickles and become hard and sticky. The symptoms of sickle cell disease includes, anemia, episodes of pain, and swelling of hands and feet. 

The growth of the global sickle cell disease treatment market is majorly driven by increase in prevalence of sickle cell disease, availability of sickle cell disease medications, and initiatives taken by government to develop better healthcare infrastructure. For instance, according to Centers for Disease Control and Prevention, sickle cell disease affects 1 of every 360 African new born and 1 in 13 babies born carries the sickle cell trait. 

However, high cost of treatment associated with sickle cell disease treatment and side effects associated with sickle cell disease may hinder the market growth. Conversely, expansion of R&D pipeline, ongoing medicine approvals, and strong growth potential in unexplored new markets are expected to provide numerous opportunities for the market growth during the forecast period.

The global sickle cell disease treatment market is segmented on the basis of drug type, type, route of administration, and region to provide a detailed assessment of the market. By drug type, it is segmented into hydroxyurea, oxbryta, adakveo, and others. The others segment further includes, endari, pain-relieving medication, and others. 

In addition, on the basis of type is segmented into sickle cell anemia or HbSS, HbSC, and others. The others segment further includes, HbS beta thalassemia, HbSD, HbSE, and HbSO. By route of administration, it is segmented into oral and parenteral. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The key market players profiled in the report include Agios Pharmaceuticals, Bristol Myers Squibb Company, CRISPR Therapeutics, Editas Medicine, Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., Medunic USA, Inc., Novartis AG, Novo Nordisk, and Vifor Pharma.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sickle cell disease treatment market analysis from 2021 to 2031 to identify the prevailing sickle cell disease treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the sickle cell disease treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global sickle cell disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

• Hydroxyurea
  • Distribution Channel
  • Hospitals Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers
• Oxybryta
• Adakveo
• Others

By Type

• Sickle Cell Anemia
• HbSC
• Others

By Route of Administration

• Oral
• Parenteral

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • Agios Pharmaceuticals
  • Bristol-Myers Squibb
  • CRISPR Therapeutics
  • editas Medicine
  • Emmaus Life Sciences, Inc.
  • Global Blood Therapeutics, Inc.
  • Medunic USA Inc.
  • Novartis AG
  • Novo Nordisk
  • Vifor Pharma

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market
• 3.7.Patent Landscape

CHAPTER 4: SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Hydroxyurea
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
  • 4.2.4 Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
    • 4.2.4.1 Hospitals Pharmacies Market size and forecast, by region
    • 4.2.4.2 Drug Stores and Retail Pharmacies Market size and forecast, by region
    • 4.2.4.3 Online Providers Market size and forecast, by region
• 4.3 Oxybryta
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country
• 4.4 Adakveo
  • 4.4.1 Key market trends, growth factors and opportunities
  • 4.4.2 Market size and forecast, by region
  • 4.4.3 Market analysis by country
• 4.5 Others
  • 4.5.1 Key market trends, growth factors and opportunities
  • 4.5.2 Market size and forecast, by region
  • 4.5.3 Market analysis by country

CHAPTER 5: SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Sickle Cell Anemia
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 HbSC
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
• 5.4 Others
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country

CHAPTER 6: SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Oral
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Parenteral
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country

CHAPTER 7: SICKLE CELL DISEASE TREATMENT MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Drug Type
    • 7.2.2.1 North America Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
  • 7.2.3 North America Market size and forecast, by Type
  • 7.2.4 North America Market size and forecast, by Route of Administration
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Drug Type
    • 7.2.5.1.2 Market size and forecast, by Type
    • 7.2.5.1.3 Market size and forecast, by Route of Administration
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Drug Type
    • 7.2.5.2.2 Market size and forecast, by Type
    • 7.2.5.2.3 Market size and forecast, by Route of Administration
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Drug Type
    • 7.2.5.3.2 Market size and forecast, by Type
    • 7.2.5.3.3 Market size and forecast, by Route of Administration
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Drug Type
    • 7.3.2.1 Europe Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
  • 7.3.3 Europe Market size and forecast, by Type
  • 7.3.4 Europe Market size and forecast, by Route of Administration
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Drug Type
    • 7.3.5.1.2 Market size and forecast, by Type
    • 7.3.5.1.3 Market size and forecast, by Route of Administration
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Drug Type
    • 7.3.5.2.2 Market size and forecast, by Type
    • 7.3.5.2.3 Market size and forecast, by Route of Administration
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Drug Type
    • 7.3.5.3.2 Market size and forecast, by Type
    • 7.3.5.3.3 Market size and forecast, by Route of Administration
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Drug Type
    • 7.3.5.4.2 Market size and forecast, by Type
    • 7.3.5.4.3 Market size and forecast, by Route of Administration
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Drug Type
    • 7.3.5.5.2 Market size and forecast, by Type
    • 7.3.5.5.3 Market size and forecast, by Route of Administration
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Drug Type
    • 7.3.5.6.2 Market size and forecast, by Type
    • 7.3.5.6.3 Market size and forecast, by Route of Administration
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Drug Type
    • 7.4.2.1 Asia-Pacific Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
  • 7.4.3 Asia-Pacific Market size and forecast, by Type
  • 7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Drug Type
    • 7.4.5.1.2 Market size and forecast, by Type
    • 7.4.5.1.3 Market size and forecast, by Route of Administration
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Drug Type
    • 7.4.5.2.2 Market size and forecast, by Type
    • 7.4.5.2.3 Market size and forecast, by Route of Administration
    • 7.4.5.3 India
    • 7.4.5.3.1 Market size and forecast, by Drug Type
    • 7.4.5.3.2 Market size and forecast, by Type
    • 7.4.5.3.3 Market size and forecast, by Route of Administration
    • 7.4.5.4 Australia
    • 7.4.5.4.1 Market size and forecast, by Drug Type
    • 7.4.5.4.2 Market size and forecast, by Type
    • 7.4.5.4.3 Market size and forecast, by Route of Administration
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Drug Type
    • 7.4.5.5.2 Market size and forecast, by Type
    • 7.4.5.5.3 Market size and forecast, by Route of Administration
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Drug Type
    • 7.4.5.6.2 Market size and forecast, by Type
    • 7.4.5.6.3 Market size and forecast, by Route of Administration
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Drug Type
    • 7.5.2.1 LAMEA Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
  • 7.5.3 LAMEA Market size and forecast, by Type
  • 7.5.4 LAMEA Market size and forecast, by Route of Administration
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Drug Type
    • 7.5.5.1.2 Market size and forecast, by Type
    • 7.5.5.1.3 Market size and forecast, by Route of Administration
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Drug Type
    • 7.5.5.2.2 Market size and forecast, by Type
    • 7.5.5.2.3 Market size and forecast, by Route of Administration
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Drug Type
    • 7.5.5.3.2 Market size and forecast, by Type
    • 7.5.5.3.3 Market size and forecast, by Route of Administration
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Drug Type
    • 7.5.5.4.2 Market size and forecast, by Type
    • 7.5.5.4.3 Market size and forecast, by Route of Administration

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 Agios Pharmaceuticals
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Bristol-Myers Squibb
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 CRISPR Therapeutics
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 editas Medicine
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Emmaus Life Sciences, Inc.
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 Global Blood Therapeutics, Inc.
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Medunic USA Inc.
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Novartis AG
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Novo Nordisk
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Vifor Pharma
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments